Chemotherapy benefit for ‘ER-positive’ breast cancer and contamination of Nonluminal subtypes—waiting for TAILORx and RxPONDER von Sun, Z., Prat, A., Cheang, M.C.U., Gelber, R.D., Perou, C.M.

Volltext

Mre11 Dysfunction Is Associated With Triple-Negative Breast Cancer and Confers Sensitivity to DNA Damaging Therapy von Gupta, G.P, Ho, A.Y, Feng, W, Fan, C, Akram, M, Brogi, E, Powell, S.N, Perou, C.M, Wen, Y.H, Petrini, J.H.J

Volltext

Radiation-induced Gene Signature Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer Patients von Oh, D.S, Chao, H.H, Balletta, L.D, Contreras, C.M, Perou, C.M

Volltext

S7 Therapeutic implications of the breast tumor intrinsic subtypes von Perou, C.M

Volltext

306: Chemotherapy sensitizes p95HER2-positive breast cancers to trastuzumab von Morancho, B, Parra-Palau, J.L, Peg, V, Vicario, R, Zacarias-Fluck, M, Pedersen, K, Perou, C.M, Prat, A, Rubio, I.T, Arribas, J

Volltext

Predictive gene profiles for breast cancer patients von Perou, C.M

Volltext

Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential von Knezevic, J, Pfefferle, A D, Petrovic, I, Greene, S B, Perou, C M, Rosen, J M

Volltext

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen von Prat, A., Parker, J.S., Fan, C., Cheang, M.C.U., Miller, L.D., Bergh, J., Chia, S.K.L., Bernard, P.S., Nielsen, T.O., Ellis, M.J., Carey, L.A., Perou, C.M.

Volltext

Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival von Tobin, N.P., Harrell, J.C., Lövrot, J., Egyhazi Brage, S., Frostvik Stolt, M., Carlsson, L., Einbeigi, Z., Linderholm, B., Loman, N., Malmberg, M., Walz, T., Fernö, M., Perou, C.M., Bergh, J., Hatschek, T., Lindström, L.S., Hatschek, Thomas, Fernö, Mårten, Lindström, Linda Sofie, Hedenfalk, Ingrid, Brandberg, Yvonne, Carstensen, John, Egyhazy, Suzanne, Stolt, Marianne Frostvik, Skoog, Lambert, Hellström, Mats, Maliniemi, Maarit, Svensson, Helene, Åström, Gunnar, Bergh, Jonas, Bjöhle, Judith, Lidbrink, Elisabet, Rotstein, Sam, Wallberg, Birgitta, Einbeigi, Zakaria, Carlsson, Per, Linderholm, Barbro, Walz, Thomas, Loman, Niklas, Malmström, Per, Söderberg, Martin, Malmberg, Martin, Carlsson, Lena, Umeå, Lindh, Birgitta, Sundqvist, Marie, Malmberg, Lena

Volltext

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer von Villacampa, G., Tung, N.M., Pernas, S., Paré, L., Bueno-Muiño, C., Echavarría, I., López-Tarruella, S., Roche-Molina, M., del Monte-Millán, M., Marín-Aguilera, M., Brasó-Maristany, F., Waks, A.G., Pascual, T., Martínez-Sáez, O., Vivancos, A., Conte, P.F., Guarneri, V., Vittoria Dieci, M., Griguolo, G., Cortés, J., Llombart-Cussac, A., Muñoz, M., Vidal, M., Adamo, B., Wolff, A.C., DeMichele, A., Villagrasa, P., Parker, J.S., Perou, C.M., Fernandez-Martinez, A., Carey, L.A., Mittendorf, E.A., Martín, M., Prat, A., Tolaney, S.M.

Volltext

339TiP SOLTI-1502 ARIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer von Manso, L., Pernas, S., Margelí, M., Blanch, S., Adamo, B., Salvador Bofill, F.J., Moreno, D., González, X., Pascual, T., Ferrero-Cafiero, J.M., Perou, C.M., Prat, A., Oliveira, M.

Volltext

268P Impact of B cell and plasma cell infiltration on survival in early-stage breast cancer (BC) without recurrence von Angelats, L., Brunet, L. Pare, Rubio-Perez, C., Torres, E. Sanfeliu, Solis, E. Segui, Villacampa, G., Marin, M., Conte, B., Saez, O. Martinez, Fernandez-Martinez, A., Buckingham, W., Guedan, S., Heyn, H., Vivancos, A., Parker, J., Gonzalez, P. Villagrasa, Perou, C.M., Prat, A., Maristany, F. Braso

Volltext

237MO TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy without immunotherapy von Jimenez, M. Martin, Gluz, O., Villacampa, G., Lopez-Tarruella Cobo, S., Nitz, U.A., Cobo, S., Brasó-Maristany, F., Christgen, M., Gilarranz, Y. Jerez, Kummel, S., Conte, B., Diaz-Guardamino, I. Echavarria, Graeser-Mayer, M.K., Kreipe, H., Del Monte-Millan, M., Lopez, B. Herrero, Perou, C.M., Brunet, L. Pare, Prat, A., Harbeck, N.

Volltext

140MO HER2DX genomic test in HER2-positive/hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analy... von Guarneri, V., Dieci, M.V., Griguolo, G., Pare Brunet, L., Marin, M., Miglietta, F., Bottosso, M., Giorgi, C.A., Blasco, P., Castillo, O., Galván, P., Jares, P., Puig-butille, J.A., Vivancos, A., Villagrasa Gonzalez, P., Parker, J., Perou, C.M., Conte, P.F., Prat, A.

Volltext

153P HER2DX risk-score in the context of the PREDICT online-tool: A correlative analysis of the Short-HER clinical trial in early-stage HER2-positive (HER2+) breast cancer (BC) von Conte, P.F., Pare Brunet, L., Brasó-Maristany, F., Chic, N., Martinez Saez, O., Dieci, M.V., Marin, M., Guarneri, V., Vivancos, A., Villagrasa Gonzalez, P., Parker, J., Perou, C.M., Prat, A.

Volltext

272TiP HARMONIA SOLTI-2101 / AFT-58: A head-to-head phase III study comparing ribociclib (RIB) and palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/... von Pascual, T., Stover, D.G., Thuerigen, A., Perou, C.M., Ciruelos, E.M., Casas Fernandez Tejerina, A., Spears, P., Roux, E., Hu, H., Lu, Y-S., Tolaney, S.M., Partridge, A., Villacampa Javierre, G., Ferrero Cafiero, J.M., Carey, L., Prat, A.

Volltext

c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer von Nair, R, Roden, D L, Teo, W S, McFarland, A, Junankar, S, Ye, S, Nguyen, A, Yang, J, Nikolic, I, Hui, M, Morey, A, Shah, J, Pfefferle, A D, Usary, J, Selinger, C, Baker, L A, Armstrong, N, Cowley, M J, Naylor, M J, Ormandy, C J, Lakhani, S R, Herschkowitz, J I, Perou, C M, Kaplan, W, O'Toole, S A, Swarbrick, A

Volltext

Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: A correlative analysis of the CALGB 40601 clinical... von Fernandez-Martinez, A., Tanioka, M., Fan, C., Parker, J.S., Hoadley, K.A., Krop, I., Partridge, A., Carey, L., Perou, C.M.

Volltext

174O - Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer: A correlative analysis of the CALGB 40601 c... von Fernandez-Martinez, A., Tanioka, M., Fan, C., Parker, J.S., Hoadley, K.A., Krop, I., Partridge, A., Carey, L., Perou, C.M.

Volltext

25P Research-based HER2DX in patients with early-stage HER2-positive (HER2+) breast cancer treated in the N9831 phase III clinical trial von Brasó-Maristany, F., Martinez Saez, O., Pare Brunet, L., Marín-Aguilera, M., Conte, P.F., Jares, P., Guarneri, V., Pascual, T., Puig-Butille, J.A., Vivancos, A., Parker, J., Villagrasa Gonzalez, P., Tolaney, S.M., Carey, L.A., Perou, C.M., Prat, A.

Volltext